Biota Message Board - Msg: 7750462

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biota

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Epicenter who wrote (30)	2/10/1999 5:18:00 AM
From: Henrik	Read Replies (1) of 46

Swedish News : BIOTA HOLDINGS LIMITED 1999-02-10 ASX ===================================================================== Yesterday Australia, Sweden today - tomorrow: The World (TV News headline in Australia today Feb. 10) ===================================================================== HOMEX - Melbourne +++++++++++++++++++++++++ Dicta Holdings Limited advises that Glaxo Wellcome has received approval from the Medical Products Agency in Sweden to market Relenza(zanamivir) for the treatment of influenza A and B. In addition,Biota was notified yesterday by the Australian Drug Evaluation Committee (ADEC) of its recommendation for approval to market Relenza for the treatment of influenza A and B. These are the first major steps in the world-wide marketing of Relenza. Sweden will now act as the Reference Member State in the Mutual Recognition Process for the purpose of obtaining approval in the other countries of the European Union. Approvals in European countries are consequently expected to follow later this year. Glaxo Wellcome is a research-based company whose people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to the healthcare providers that serve them. Biota is an Australian listed company (BTA) based in Melbourne and engaged in the funding and management of a research and development program focusing principally on the discovery of new human pharmaceuticals for the treatment of viral respiratory diseases and cancer. The company's ADRs trade in the US on the pink sheets at a ratio of three shares to each ADR. For further information please contact: Dr. Hugh Niall Elizabeth Field/Michael Moore Chief Executive Officer Turnbull Porter Novelli Biota Holdings Limited Telephone: 61 3 9289 9555 Telephone:61 3 9529 2311

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next